Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Clovis Oncology Inc (CLVS)

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 711,327
  • Shares Outstanding, K 53,005
  • Annual Sales, $ 95,390 K
  • Annual Income, $ -368,010 K
  • 60-Month Beta 1.99
  • Price/Sales 7.41
  • Price/Cash Flow N/A
  • Price/Book 9.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -1.69
  • Number of Estimates 6
  • High Estimate -1.56
  • Low Estimate -1.89
  • Prior Year -1.94
  • Growth Rate Est. (year over year) +12.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.75 +1.49%
on 06/14/19
16.98 -23.79%
on 05/28/19
-3.80 (-22.70%)
since 05/24/19
3-Month
12.75 +1.49%
on 06/14/19
25.88 -50.00%
on 04/08/19
-10.61 (-45.05%)
since 03/26/19
52-Week
11.50 +12.52%
on 10/31/18
50.00 -74.12%
on 07/09/18
-31.90 (-71.14%)
since 06/26/18

Most Recent Stories

More News
After Yesterday's Decline of 9.64%, Clovis Oncology Offers Investors Better Value

Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $13.58 to a high of $14.81. Yesterday, the shares fell 9.6%, which took the trading range below the 3-day low of $14.03...

CLVS : 13.12 (-2.24%)
Pfizer's Talzenna Gets Approval in Europe for Breast Cancer

Pfizer's (PFE) PARP inhibitor, Talzenna, receives approval in Europe for treating BRCA-mutated locally advanced or metastatic breast cancer.

AZN : 40.89 (-1.23%)
BMRN : 83.05 (-0.92%)
CLVS : 13.12 (-2.24%)
PFE : 43.10 (-1.51%)
Clovis Oncology Down 38.0% Since SmarTrend Downtrend Call (CLVS)

SmarTrend identified a Downtrend for Clovis Oncology (NASDAQ:CLVS) on March 25th, 2019 at $23.84. In approximately 3 months, Clovis Oncology has returned 38.05% as of today's recent price of $14.77.

CLVS : 13.12 (-2.24%)
Clovis Oncology Falls 2.61% on Heavy Volume: Watch For Potential Rebound

Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $14.25 to a high of $14.54. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $14.79...

CLVS : 13.12 (-2.24%)
Why Is Clovis (CLVS) Down 25.3% Since Last Earnings Report?

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CLVS : 13.12 (-2.24%)
Clovis Oncology Shares Down 31.0% Since SmarTrend's Sell Call (CLVS)

SmarTrend identified a Downtrend for Clovis Oncology (NASDAQ:CLVS) on March 25th, 2019 at $23.84. In approximately 2 months, Clovis Oncology has returned 31.00% as of today's recent price of $16.45.

CLVS : 13.12 (-2.24%)
Downtrend Call Working As Clovis Oncology Stock Falls 31.4% (CLVS)

SmarTrend identified a Downtrend for Clovis Oncology (NASDAQ:CLVS) on March 25th, 2019 at $23.84. In approximately 2 months, Clovis Oncology has returned 31.38% as of today's recent price of $16.36.

CLVS : 13.12 (-2.24%)
Clovis Oncology Presents Patient-Centered Outcomes Data from Phase 3 ARIEL3 Study for Rubraca(R) in Advanced Ovarian Cancer

--Data presented at the International Society for Pharmacoeconomics and Outcomes (ISPOR) 2019 Annual Meeting

CLVS : 13.12 (-2.24%)
Clovis Oncology Announces Presentations at 2019 ASCO Annual Meeting

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that four abstracts featuring data for Rubraca(R) (rucaparib) and ongoing studies in multiple tumor types will be presented at the 2019...

CLVS : 13.12 (-2.24%)
Shares of CLVS Down 16.2% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Clovis Oncology (NASDAQ:CLVS) on March 25th, 2019 at $23.84. In approximately 1 month, Clovis Oncology has returned 16.19% as of today's recent price of $19.98.

CLVS : 13.12 (-2.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CLVS with:

Business Summary

Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations....

See More

Key Turning Points

2nd Resistance Point 14.10
1st Resistance Point 13.76
Last Price 13.10
1st Support Level 13.18
2nd Support Level 12.95

See More

52-Week High 50.00
Fibonacci 61.8% 35.29
Fibonacci 50% 30.75
Fibonacci 38.2% 26.21
Last Price 13.10
52-Week Low 11.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar